{"id":84661,"date":"2023-11-15T00:49:26","date_gmt":"2023-11-15T05:49:26","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/employer-coverage-of-glp-1-drugs-for-weight-loss-lags-far-behind-diabetes-coverage-survey-finds\/"},"modified":"2023-11-15T00:49:28","modified_gmt":"2023-11-15T05:49:28","slug":"employer-coverage-of-glp-1-drugs-for-weight-loss-lags-far-behind-diabetes-coverage-survey-finds","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=84661","title":{"rendered":"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0"},"content":{"rendered":"
\n

For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that class of drugs for diabetes, a new survey shows.\u00a0<\/p>\n

While more than three-quarters of employer-sponsored plans are covering these drugs for diabetes, only about one in four are covering the medications for weight loss, according to the survey conducted in late October by the International Foundation of Employee Benefit Plans, a nonprofit research and education organization. And only 13% of the more than 200 employer plans surveyed said they were considering covering GLP-1 drugs for weight loss.\u00a0<\/p>\n

\n

Those findings take on fresh significance in light of mounting evidence of GLP-1 drugs\u2019 potential benefits in patients who do not have diabetes. Novo Nordisk
\n NVO,
\n -1.57%<\/bg-quote>
\n on Saturday released new clinical trial data showing that Wegovy significantly cut the risk of major cardiovascular problems in people who do not have a history of diabetes but who previously had a heart attack, stroke, or peripheral-artery disease. The American Medical Association on Tuesday said it would urge health insurers to cover weight-loss drugs approved by the U.S. Food and Drug Administration, including GLP-1 medications. \u201cThe AMA regards obesity as a disease that poses a major health concern in the United States,\u201d the group said in a statement.\u00a0<\/p>\n

In the employee-benefit foundation\u2019s survey, employers cited obesity\u2019s link with chronic diseases and associated costs as the top factor influencing decisions on GLP-1 coverage.\u00a0<\/p>\n

But the survey found that only 27% of employer plans cover GLP-1 drugs for weight loss, a figure that\u2019s up only slightly from the 22% who said they offer such coverage in a survey conducted by the employee-benefit foundation in the late spring and summer of 2022. The surveyed employer plans ranged in size from fewer than 50 to more than 10,000 active participants.\u00a0<\/p>\n

Employer-sponsored plans are the most common form of health insurance, covering nearly half of all people in the U.S., according to KFF, a health-policy research nonprofit. <\/p>\n

Many employers are holding back on weight-loss drug coverage because of concerns about the cost of GLP-1 medications and uncertainty about how long people might need to stay on them, said Julie Stich, the employee-benefit foundation\u2019s vice president of content. More than half of employers surveyed said long-term costs factored into their GLP-1 coverage decisions for obesity.\u00a0<\/p>\n

The FDA\u2019s approval last week of a new Eil Lilly & Co.
\n LLY,
\n -0.12%<\/bg-quote>
\n obesity drug, Zepbound, could affect employers\u2019 decision-making, Stich said. Lilly said the list price for Zepbound will be roughly 20% lower than Wegovy\u2019s. Employers \u201cwill sit up and take note of this lower list price,\u201d because costs are such a big factor in their decision-making, Stich said.\u00a0<\/p>\n

Some employers may be waiting for recommendations from consultants or pharmacy benefit managers before deciding to cover these drugs for weight loss, Stich said.<\/p>\n

Many employers may also be taking a wait-and-see approach, Stich said, hoping that even lower-cost options will come along. Lilly, Pfizer Inc.
\n PFE,
\n +0.97%<\/bg-quote>
\n and other drugmakers are working on oral versions of GLP-1 drugs, which may be cheaper and more accessible than the injectables available today.\u00a0<\/p>\n

Among employer plans that do cover GLP-1 drugs for weight loss, nearly 80% are controlling costs through some form of utilization management, such as requiring prior authorization or limiting coverage to people above a certain body mass index, the survey found.\u00a0<\/p>\n

For employers that cover the drugs for weight loss, those claims account for roughly 7% of total 2023 claims, on average, according to the survey.<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that class of drugs for diabetes, a new survey shows.\u00a0 While more than three-quarters of employer-sponsored plans are covering these drugs for diabetes, only about one in four are covering the medications for […]<\/p>\n","protected":false},"author":1,"featured_media":84662,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-84661","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"\nEmployer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0 | iFintechWorld<\/title>\n<meta name=\"description\" content=\"For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=84661\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0 | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=84661\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-15T05:49:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-15T05:49:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/11\/1700027367_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=84661#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=84661\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0\",\"datePublished\":\"2023-11-15T05:49:26+00:00\",\"dateModified\":\"2023-11-15T05:49:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=84661\"},\"wordCount\":601,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=84661#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=84661\",\"url\":\"https:\/\/ifintechworld.com\/?p=84661\",\"name\":\"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0 | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-11-15T05:49:26+00:00\",\"dateModified\":\"2023-11-15T05:49:28+00:00\",\"description\":\"For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=84661#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=84661\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=84661#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0 | iFintechWorld","description":"For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=84661","og_locale":"en_US","og_type":"article","og_title":"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0 | iFintechWorld","og_description":"For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that","og_url":"https:\/\/ifintechworld.com\/?p=84661","og_site_name":"iFintechWorld","article_published_time":"2023-11-15T05:49:26+00:00","article_modified_time":"2023-11-15T05:49:28+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/11\/1700027367_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=84661#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=84661"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0","datePublished":"2023-11-15T05:49:26+00:00","dateModified":"2023-11-15T05:49:28+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=84661"},"wordCount":601,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=84661#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=84661","url":"https:\/\/ifintechworld.com\/?p=84661","name":"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0 | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-11-15T05:49:26+00:00","dateModified":"2023-11-15T05:49:28+00:00","description":"For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=84661#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=84661"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=84661#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/84661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=84661"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/84661\/revisions"}],"predecessor-version":[{"id":84663,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/84661\/revisions\/84663"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/84662"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=84661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=84661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=84661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}